Viking Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Viking Therapeutics

29/07/2026 22:54

Viking Therapeutics Inc VKTX.OQ reported a quarterly adjusted loss of $1.10​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -58 cents.  The mean expectation of nineteen analysts for the quarter was for a loss of $1.25 per share. Wall Street expected results to range from $-1.39 to -83 cents per share.
Reported revenue was zero​; analysts expected zero. 
Viking Therapeutics Inc's reported EPS for the quarter was a loss of $1.10​.
The company reported a quarterly loss of $128.02 million.
Viking Therapeutics Inc shares had fallen by 13.2% this quarter and lost 3.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 9.1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Viking Therapeutics Inc is $97.50, about 65.3% above its last closing price of $33.86
This summary was machine generated from LSEG data July 29 at 09:54 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.25
-1.10
Beat
Mar. 31 2026 
-1.01
-1.37
Missed
Dec. 31 2025 
-0.89
-1.38
Missed
Sep. 30 2025 
-0.68
-0.81
Missed